Influence of leukotriene pathway polymorphisms on response to montelukast in asthma.

RATIONALE Interpatient variability in montelukast response may be related to variation in leukotriene pathway candidate genes. OBJECTIVE To determine associations between polymorphisms in leukotriene pathway candidate genes with outcomes in patients with asthma receiving montelukast for 6 mo who participated in a clinical trial. METHODS Polymorphisms were typed using Sequenom matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass array spectrometry and published methods; haplotypes were imputed using single nucleotide polymorphism-expectation maximization (SNP-EM). Analysis of variance and logistic regression models were used to test for changes in outcomes by genotype. In addition, chi(2) and likelihood ratio tests were used to test for differences between groups. Case-control comparisons were analyzed using the SNP-EM Omnibus likelihood ratio test. MEASUREMENTS Outcomes were asthma exacerbation rate and changes in FEV(1) compared with baseline. RESULTS DNA was collected from 252 participants: 69% were white, 26% were African American. Twenty-eight SNPs in the ALOX5, LTA4H, LTC4S, MRP1, and cysLT1R genes, and an ALOX5 repeat polymorphism were successfully typed. There were racial disparities in allele frequencies in 17 SNPs and in the repeat polymorphism. Association analyses were performed in 61 whites. Associations were found between genotypes of SNPs in the ALOX5 (rs2115819) and MRP1 (rs119774) genes and changes in FEV(1) (p < 0.05), and between two SNPs in LTC4S (rs730012) and in LTA4H (rs2660845) genes for exacerbation rates. Mutant ALOX5 repeat polymorphism was associated with decreased exacerbation rates. There was strong linkage disequilibrium between ALOX5 SNPs. Associations between ALOX5 haplotypes and risk of exacerbations were found. CONCLUSIONS Genetic variation in leukotriene pathway candidate genes contributes to variability in montelukast response.

[1]  I. Hall,et al.  5-Lipoxygenase polymorphism and in-vivo response to leukotriene receptor antagonists , 2002, European Journal of Clinical Pharmacology.

[2]  Third Expert Panel on theDiagnosis,et al.  Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma , 1997 .

[3]  D. Postma,et al.  ATP-binding cassette (ABC) transporters in normal and pathological lung , 2005, Respiratory research.

[4]  N. Kissoon,et al.  Effect of montelukast on time‐course of exhaled nitric oxide in asthma: Influence of LTC4 synthase A−444C polymorphism , 2003, Pediatric pulmonology.

[5]  A. Sekine,et al.  Identification of 779 genetic variations in eight genes encoding members of the ATP-binding cassette, subfamily C (ABCC/MRP/CFTR) , 2002, Journal of Human Genetics.

[6]  G H Guyatt,et al.  Development and validation of a questionnaire to measure asthma control. , 1999, The European respiratory journal.

[7]  Brigit VanGraafeiland,et al.  National Asthma Education and Prevention Program. , 2002, The Nurse practitioner.

[8]  Bengt Samuelsson,et al.  Leukotrienes are potent constrictors of human bronchi , 1980, Nature.

[9]  W. Busse,et al.  Cysteinyl leukotrienes in allergic inflammation: strategic target for therapy. , 2005, Chest.

[10]  V. Jala,et al.  Leukotrienes and atherosclerosis: new roles for old mediators. , 2004, Trends in immunology.

[11]  Nicholas Schork,et al.  Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment , 1999, Nature Genetics.

[12]  K. Tantisira,et al.  The pharmacogenetics of asthma: an update. , 2005, Current opinion in molecular therapeutics.

[13]  E. Israel,et al.  Effects of montelukast and beclomethasone on airway function and asthma control. , 2002, The Journal of allergy and clinical immunology.

[14]  M. Sanak,et al.  Enhanced expression of the leukotriene C(4) synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma. , 2000, American journal of respiratory cell and molecular biology.

[15]  J. Banks,et al.  Characterization of Within-Subject Responses to Fluticasone and Montelukast in Childhood Asthma , 2006, Pediatrics.

[16]  I. Sayers,et al.  Promoter polymorphism in the 5‐lipoxygenase (ALOX5) and 5‐lipoxygenase‐activating protein (ALOX5AP) genes and asthma susceptibility in a Caucasian population , 2003, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[17]  T. Green,et al.  Montelukast Reduces Asthma Exacerbations in 2- to 5-Year-Old Children With Intermittent Asthma , 2006, Pediatrics.

[18]  S. Bolk,et al.  The pharmacogenetics of asthma: a candidate gene approach , 2001, The Pharmacogenomics Journal.

[19]  D A Revicki,et al.  Integrating patient preferences into health outcomes assessment: the multiattribute Asthma Symptom Utility Index. , 1998, Chest.

[20]  L M Smith,et al.  Analysis of single nucleotide polymorphisms by primer extension and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. , 2000, Rapid communications in mass spectrometry : RCM.

[21]  Y. Kanaoka,et al.  Cysteinyl Leukotrienes and Their Receptors: Cellular Distribution and Function in Immune and Inflammatory Responses1 , 2004, The Journal of Immunology.

[22]  J. W. Woods,et al.  5-lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes , 1993, The Journal of experimental medicine.

[23]  C. Austin,et al.  Expression of the cysteinyl leukotriene 1 receptor in normal human lung and peripheral blood leukocytes. , 2001, American journal of respiratory and critical care medicine.

[24]  E. Silverman,et al.  Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. , 1997, The Journal of clinical investigation.

[25]  I. Sayers,et al.  Variant LTC4 synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast , 2000, Thorax.

[26]  J. Bernaudin,et al.  Different Pattern of MRP Localization in Ciliated and Basal Cells from Human Bronchial Epithelium , 1998, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[27]  N. Schork,et al.  Genetic analysis of case/control data using estimated haplotype frequencies: application to APOE locus variation and Alzheimer's disease. , 2001, Genome research.

[28]  K. Hung,et al.  A new MALDI-TOF based mini-sequencing assay for genotyping of SNPS. , 2000, Nucleic acids research.

[29]  J. Pritchard,et al.  Use of unlinked genetic markers to detect population stratification in association studies. , 1999, American journal of human genetics.

[30]  E. Israel,et al.  Treatment of asthma with drugs modifying the leukotriene pathway. , 1999, The New England journal of medicine.

[31]  M. Sanak,et al.  Montelukast for persistent asthma , 2001, The Lancet.

[32]  J. Drazen.  Clinical pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors. , 1998, American journal of respiratory and critical care medicine.

[33]  E. Boerwinkle,et al.  High‐throughput multiplex SNP genotyping with MALDI‐TOF mass spectrometry: Practice, problems and promise , 2001, Human mutation.

[34]  M. Daly,et al.  Genome-wide association studies for common diseases and complex traits , 2005, Nature Reviews Genetics.

[35]  T. Uchiumi,et al.  Enhanced transport of anticancer agents and leukotriene C4 by the human canalicular multispecific organic anion transporter (cMOAT/MRP2) , 1999, FEBS letters.

[36]  Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. , 2004 .

[37]  Yusuke Suzuki,et al.  Leukotriene C4 synthase gene A(-444)C polymorphism and clinical response to a CYS-LT(1) antagonist, pranlukast, in Japanese patients with moderate asthma. , 2002, Pharmacogenetics.

[38]  Lynn Wei,et al.  Oral Montelukast, Inhaled Beclomethasone, and Placebo for Chronic Asthma , 1999, Annals of Internal Medicine.

[39]  N. Schork,et al.  Accuracy of haplotype frequency estimation for biallelic loci, via the expectation-maximization algorithm for unphased diploid genotype data. , 2000, American journal of human genetics.

[40]  M. Anderson,et al.  Interconversion of leukotrienes catalyzed by purified gamma-glutamyl transpeptidase: concomitant formation of leukotriene D4 and gamma-glutamyl amino acids. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[41]  J. Haeggström,et al.  Structure, function, and regulation of leukotriene A4 hydrolase. , 2000, American journal of respiratory and critical care medicine.

[42]  S. Higuchi,et al.  Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. , 2001, Pharmacogenetics.

[43]  A. Nayak.  A review of montelukast in the treatment of asthma and allergic rhinitis , 2004, Expert opinion on pharmacotherapy.

[44]  G. Currie,et al.  Uncertain biologic relevance of polymorphisms of leukotriene C4 synthase in asthma. , 2005, The Journal of allergy and clinical immunology.

[45]  E. Corey,et al.  Conversion of leukotriene D4 to leukotriene E4 by a dipeptidase released from the specific granule of human polymorphonuclear leucocytes. , 1983, Immunology.

[46]  J. Drazen,et al.  Leukotrienes and airway responses. , 1987, The American review of respiratory disease.

[47]  M. A. Bray,et al.  Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes , 1980, Nature.

[48]  J. Holloway,et al.  Polymorphism of tandem repeat in promoter of 5‐lipoxygenase in ASA‐intolerant asthma: a positive association with airway hyperresponsiveness , 2005, Allergy.

[49]  Robert A. Lewis,et al.  Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. , 1990, The New England journal of medicine.

[50]  E. Silverman,et al.  Heterogeneity of therapeutic responses in asthma. , 2000, British medical bulletin.

[51]  Guy Perrière,et al.  EMGLib: the Enhanced Microbial Genomes Library (update 2000) , 2000, Nucleic Acids Res..

[52]  B. Lipworth,et al.  Leukotriene C4 synthase polymorphisms and responsiveness to leukotriene antagonists in asthma. , 2003, British journal of clinical pharmacology.

[53]  W. Owen,et al.  The identification of a distinct export step following the biosynthesis of leukotriene C4 by human eosinophils. , 1989, The Journal of biological chemistry.